Initial Public Offering
Baird served as a book-running manager on this offering
AboutProgenity, Inc. (“Progenity” or the “Company”) (NASDAQ-GM:PROG) recently completed an initial public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds from the offering are expected to be $100.0 million. In addition, Progenity has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the initial public offering price.
Progenity expects to use the proceeds of this offering to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform and for working capital and general corporate purposes.
Progenity is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The Company applies a multi-omics approach, combining genomics, epigenomics, proteomics and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. Progenity, Inc. is headquartered in San Diego, California.
CONTACT US TO LEARN MORE
- June 2020
- Progenity, Inc.
- Target Location
- North America